Aaron Y. Chang

Aaron Y. Chang

Auto-generated profile, based on publicly available information

Aaron Y. Chang

Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2020 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
PMPatrizia Mondello
Patrizia Mondello
STSaber Tadros
Saber Tadros
MTMatt Teater
Matt Teater
LFLorena Fontan
Lorena Fontan
ACAaron Y. Chang
Aaron Y. Chang
Michael GreenMichael Green
Michael Green
CREBBP mutations are highly recurrent in B-cell lymphomas and either inactivate its histone acetyltransferase (HAT) domain or truncate the protein. Herein, we show that these two classes of mutations yield different degrees of disruption of the epigenome, with HAT mutations being more severe and associated with inferior clinical outcome. Genes perturbed by CREBBP mutation are direct targets of the BCL6–HDAC3 onco-repressor complex. Accordingly, we show that HDAC3-selective inhibitors reverse CREBBP-mutant aberrant epigenetic programming, resulting in: (i) growth inhibition of lymphoma cells through induction of BCL6 target genes such as CDKN1A and (ii) restoration of immune surveillance due to induction of BCL6-repressed IFN pathway and antigen-presenting genes. By reactivating these genes, exposure to HDAC3 inhibitors restored the ability of tumor-infiltrating lymphocytes to kill DLBCL cells in an MHC class I and II–dependent manner, and synergized with PD-L1 blockade in a syngeneic model in vivo. Hence, HDAC3 inhibition represents a novel mechanism-based immune epigenetic therapy for CREBBP-mutant lymphomas. Significance: We have leveraged the molecular characterization of different types of CREBBP mutations to define a rational approach for targeting these mutations through selective inhibition of HDAC3. This represents an attractive therapeutic avenue for targeting synthetic vulnerabilities in CREBBP-mutant cells in tandem with promoting antitumor immunity. This article is highlighted in the In This Issue feature, p. 327

30 November 2018 in eLife
Verified
Journal Article
Open access
RGRon S Gejman
Ron S Gejman
ACAaron Y Chang
Aaron Y Chang
HJHeather F Jones
Heather F Jones
KDKrysta DiKun
Krysta DiKun
AHAbraham Ari Hakimi
Abraham Ari Hakimi
DSDavid A Scheinberg
David A Scheinberg
Tumors often co-exist with T cells that recognize somatically mutated peptides presented by cancer cells on major histocompatibility complex I (MHC-I). However, it is unknown why the immune system fails to eliminate immune-recognizable neoplasms before they manifest as frank disease. To understand the determinants of MHC-I peptide immunogenicity in nascent tumors, we tested the ability of thousands of MHC-I ligands to cause tumor subclone rejection in immunocompetent mice by use of a new ‘PresentER’ antigen presentation platform. Surprisingly, we show that immunogenic tumor antigens do not lead to immune-mediated cell rejection when the fraction of cells bearing each antigen (‘clonal fraction’) is low. Moreover, the clonal fraction necessary to lead to rejection of immunogenic tumor subclones depends on the antigen. These data indicate that tumor neoantigen heterogeneity has an underappreciated impact on immune elimination of cancer cells and has implications for the design of immunotherapeutics such as cancer vaccines.

30 December 2021 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
TGThomas J. Gardner
Thomas J. Gardner
JLJ. Peter Lee
J. Peter Lee
CBCHRISTOPHER Bourne
CHRISTOPHER Bourne
DWDinali Wijewarnasuriya
Dinali Wijewarnasuriya
NKNihar Kinarivala
Nihar Kinarivala
DSDavid A. Scheinberg
David A. Scheinberg

1 December 2019 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
COClaire Y. Oh
Claire Y. Oh
MKMartin G. Klatt
Martin G. Klatt
CBChristopher Bourne
Christopher Bourne
TDTao Dao
Tao Dao
MDMegan M. Dacek
Megan M. Dacek
DSDavid A. Scheinberg
David A. Scheinberg
T-cell immunotherapies are often thwarted by the limited presentation of tumor-specific antigens abetted by the downregulation of human leukocyte antigen (HLA). We showed that drugs inhibiting ALK and RET produced dose-related increases in cell-surface HLA in tumor cells bearing these mutated kinases in vitro and in vivo, as well as elevated transcript and protein expression of HLA and other antigen-processing machinery. Subsequent analysis of HLA-presented peptides after ALK and RET inhibitor treatment identified large changes in the immunopeptidome with the appearance of hundreds of new antigens, including T-cell epitopes associated with impaired peptide processing (TEIPP) peptides. ALK inhibition additionally decreased PD-L1 levels by 75%. Therefore, these oncogenes may enhance cancer formation by allowing tumors to evade the immune system by downregulating HLA expression. Altogether, RET and ALK inhibitors could enhance T-cell–based immunotherapies by upregulating HLA, decreasing checkpoint blockade ligands, and revealing new, immunogenic, cancer-associated antigens.

17 March 2020 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
RGRon S. Gejman
Ron S. Gejman
HJHeather F. Jones
Heather F. Jones
MKMartin G. Klatt
Martin G. Klatt
ACAaron Y. Chang
Aaron Y. Chang
COClaire Y. Oh
Claire Y. Oh
DSDavid A. Scheinberg
David A. Scheinberg
T-cell receptor (TCR)–based therapeutic cells and agents have emerged as a new class of effective cancer therapies. These therapies work on cells that express intracellular cancer-associated proteins by targeting peptides displayed on MHC receptors. However, cross-reactivities of these agents to off-target cells and tissues have resulted in serious, sometimes fatal, adverse events. We have developed a high-throughput genetic platform (termed “PresentER”) that encodes MHC-I peptide minigenes for functional immunologic assays and determines the reactivities of TCR-like therapeutic agents against large libraries of MHC-I ligands. In this article, we demonstrated that PresentER could be used to identify the on-and-off targets of T cells and TCR-mimic (TCRm) antibodies using in vitro coculture assays or binding assays. We found dozens of MHC-I ligands that were cross-reactive with two TCRm antibodies and two native TCRs and that were not easily predictable by other methods.

8 February 2024 in Blood
Verified
Journal Article
Closed access
PDF file
TDTao Dao
Tao Dao
GXGuangyan Xiong
Guangyan Xiong
SMSung Soo Mun
Sung Soo Mun
JMJeremy Meyerberg
Jeremy Meyerberg
TKTatyana Korontsvit
Tatyana Korontsvit
DSDavid A. Scheinberg
David A. Scheinberg
Chimeric antigen receptor T-cell (CAR T) therapy has produced remarkable clinical responses in B-cell neoplasms. However, many challenges limit this class of agents for the treatment of other cancer types, in particular the lack of tumor-selective antigens for solid tumors and other hematological malignancies, such as acute myeloid leukemia (AML), which may be addressed without significant risk of severe toxicities while providing sufficient abundance for efficient tumor suppression. One approach to overcome this hurdle is dual targeting by an antibody–T-cell receptor (AbTCR) and a chimeric costimulatory signaling receptor (CSR) to 2 different antigens, in which both antigens are found together on the cancer cells but not together on normal cells. To explore this proof of concept in AML, we engineered a new T-cell format targeting Wilms tumor 1 protein (WT1) and CD33; both are highly expressed on most AML cells. Using an AbTCR comprising a newly developed TCR-mimic monoclonal antibody against the WT1 RMFPNAPYL (RMF) epitope/HLA-A2 complex, ESK2, and a secondary CSR comprising a single-chain variable fragment directed to CD33 linked to a truncated CD28 costimulatory fragment, this unique platform confers specific T-cell cytotoxicity to the AML cells while sparing healthy hematopoietic cells, including CD33+ myelomonocytic normal cells. These data suggest that this new platform, named AbTCR-CSR, through the combination of a AbTCR CAR and CSR could be an effective strategy to reduce toxicity and improve specificity and clinical outcomes in adoptive T-cell therapy in AML.